C-Rad AB (publ)
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solut… Read more
C-Rad AB (publ) (CRAD-B) - Net Assets
Latest net assets as of December 2025: Skr347.20 Million SEK
Based on the latest financial reports, C-Rad AB (publ) (CRAD-B) has net assets worth Skr347.20 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr500.80 Million) and total liabilities (Skr153.60 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr347.20 Million |
| % of Total Assets | 69.33% |
| Annual Growth Rate | 14.44% |
| 5-Year Change | 50.24% |
| 10-Year Change | 391.77% |
| Growth Volatility | 50.48 |
C-Rad AB (publ) - Net Assets Trend (2008–2025)
This chart illustrates how C-Rad AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for C-Rad AB (publ) (2008–2025)
The table below shows the annual net assets of C-Rad AB (publ) from 2008 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr347.20 Million | +6.83% |
| 2024-12-31 | Skr324.99 Million | +15.41% |
| 2023-12-31 | Skr281.60 Million | +16.10% |
| 2022-12-31 | Skr242.54 Million | +4.96% |
| 2021-12-31 | Skr231.09 Million | +15.67% |
| 2020-12-31 | Skr199.79 Million | +139.74% |
| 2019-12-31 | Skr83.33 Million | -11.01% |
| 2018-12-31 | Skr93.64 Million | +31.14% |
| 2017-12-31 | Skr71.41 Million | +1.14% |
| 2016-12-31 | Skr70.60 Million | +76.30% |
| 2015-12-31 | Skr40.05 Million | +0.02% |
| 2014-12-31 | Skr40.04 Million | +5.29% |
| 2013-12-31 | Skr38.03 Million | +133.82% |
| 2012-12-31 | Skr16.26 Million | -54.84% |
| 2011-12-31 | Skr36.02 Million | -25.15% |
| 2010-12-31 | Skr48.12 Million | +61.38% |
| 2009-12-31 | Skr29.82 Million | -14.93% |
| 2008-12-31 | Skr35.05 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to C-Rad AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2336639900.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | Skr347.20 Million | 100.00% |
| Total Equity | Skr347.20 Million | 100.00% |
C-Rad AB (publ) Competitors by Market Cap
The table below lists competitors of C-Rad AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AOPEN Inc
TW:3046
|
$56.67 Million |
|
Shanghai Industrial Urban Development Group Limited
PINK:SIUDF
|
$56.67 Million |
|
Value Grupo Financiero S.A.B. de C.V
MX:VALUEGFO
|
$56.69 Million |
|
Chips&Media Inc
KQ:094360
|
$56.70 Million |
|
Tapdi Oksijen AS
IS:TNZTP
|
$56.66 Million |
|
Ekachai Medical Care Public Company Limited
BK:EKH
|
$56.66 Million |
|
S.Y.PANEL Co Ltd
KQ:109610
|
$56.65 Million |
|
CIG WIRELESS
F:6CW
|
$56.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in C-Rad AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 325,000,000 to 347,200,000, a change of 22,200,000 (6.8%).
- Net income of 10,500,000 contributed positively to equity growth.
- Share repurchases of 11,500,000 reduced equity.
- New share issuances of 400,000 increased equity.
- Other comprehensive income increased equity by 1,807,000.
- Other factors increased equity by 20,993,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr10.50 Million | +3.02% |
| Share Repurchases | Skr11.50 Million | -3.31% |
| Share Issuances | Skr400.00K | +0.12% |
| Other Comprehensive Income | Skr1.81 Million | +0.52% |
| Other Changes | Skr20.99 Million | +6.05% |
| Total Change | Skr- | 6.83% |
Book Value vs Market Value Analysis
This analysis compares C-Rad AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.51x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 7.09x to 2.51x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | Skr3.65 | Skr25.85 | x |
| 2009-12-31 | Skr2.65 | Skr25.85 | x |
| 2010-12-31 | Skr3.38 | Skr25.85 | x |
| 2011-12-31 | Skr2.01 | Skr25.85 | x |
| 2012-12-31 | Skr0.88 | Skr25.85 | x |
| 2013-12-31 | Skr1.81 | Skr25.85 | x |
| 2014-12-31 | Skr1.84 | Skr25.85 | x |
| 2015-12-31 | Skr1.70 | Skr25.85 | x |
| 2016-12-31 | Skr2.75 | Skr25.85 | x |
| 2017-12-31 | Skr2.40 | Skr25.85 | x |
| 2018-12-31 | Skr3.03 | Skr25.85 | x |
| 2019-12-31 | Skr2.69 | Skr25.85 | x |
| 2020-12-31 | Skr6.00 | Skr25.85 | x |
| 2021-12-31 | Skr6.81 | Skr25.85 | x |
| 2022-12-31 | Skr7.18 | Skr25.85 | x |
| 2023-12-31 | Skr8.34 | Skr25.85 | x |
| 2024-12-31 | Skr9.61 | Skr25.85 | x |
| 2025-12-31 | Skr10.28 | Skr25.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently C-Rad AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.02%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.38%
- • Asset Turnover: 0.88x
- • Equity Multiplier: 1.44x
- Recent ROE (3.02%) is above the historical average (-24.78%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -30.59% | -830.50% | 0.03x | 1.38x | Skr-14.23 Million |
| 2009 | -34.38% | -209.25% | 0.11x | 1.50x | Skr-13.23 Million |
| 2010 | -20.45% | -69.11% | 0.21x | 1.41x | Skr-14.65 Million |
| 2011 | -118.30% | -285.76% | 0.28x | 1.51x | Skr-46.21 Million |
| 2012 | -119.22% | -75.22% | 0.68x | 2.34x | Skr-21.02 Million |
| 2013 | -55.21% | -46.62% | 0.73x | 1.62x | Skr-24.80 Million |
| 2014 | -15.73% | -11.84% | 0.73x | 1.81x | Skr-10.30 Million |
| 2015 | -52.90% | -32.02% | 0.90x | 1.84x | Skr-25.19 Million |
| 2016 | -44.20% | -37.76% | 0.81x | 1.45x | Skr-38.27 Million |
| 2017 | -15.27% | -8.19% | 1.13x | 1.65x | Skr-18.05 Million |
| 2018 | 22.63% | 11.15% | 1.30x | 1.57x | Skr11.83 Million |
| 2019 | -16.56% | -6.72% | 1.30x | 1.89x | Skr-22.13 Million |
| 2020 | 7.19% | 6.48% | 0.82x | 1.35x | Skr-5.61 Million |
| 2021 | 10.86% | 9.61% | 0.85x | 1.33x | Skr1.99 Million |
| 2022 | 3.08% | 2.48% | 0.89x | 1.40x | Skr-16.78 Million |
| 2023 | 12.61% | 8.37% | 1.05x | 1.43x | Skr7.36 Million |
| 2024 | 17.37% | 12.04% | 0.96x | 1.51x | Skr23.95 Million |
| 2025 | 3.02% | 2.38% | 0.88x | 1.44x | Skr-24.22 Million |
Industry Comparison
This section compares C-Rad AB (publ)'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $73,150,807
- Average return on equity (ROE) among peers: -85.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| C-Rad AB (publ) (CRAD-B) | Skr347.20 Million | -30.59% | 0.44x | $56.67 Million |
| Acarix A/S (ACARIX) | $76.60 Million | -60.65% | 0.08x | $28.86 Million |
| Arcoma AB (ARCOMA) | $12.52 Million | -92.85% | 4.66x | $8.93 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $353.18 Million | -39.18% | 0.87x | $19.20 Million |
| CellaVision AB (CEVI) | $20.07 Million | 13.08% | 1.20x | $262.59 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $65.69 Million | -72.50% | 0.20x | $13.78 Million |
| Chordate Medical Holding AB (CMH) | $38.95 Million | -55.88% | 0.13x | $17.64K |
| Coala Life Group AB (COALA) | $52.33 Million | -287.99% | 0.53x | $468.93K |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $34.43K |
| Episurf Medical AB (publ) (EPIS-B) | $41.40 Million | -170.53% | 0.39x | $5.40 Million |